CD8A and neoplasm: Pretreatment expression of PD-L1 on peripheral CD8+ T cells had a significant positive association with tumor response to triple therapy using RT+L19–IL2+anti-PD-L1 (p=0.044), indicating that subjects with a higher peripheral expression of PD-L1 required a longer time to reach endpoint after triple therapy.